Clinical Trial

A Long-term Administration Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Schizophrenia

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated October 30, 2024 (before its estimated August 2025 completion). Its status may not reflect the trial's current state.
Summary
Confirm the tolerability and safety of long-term administration of the brexpiprazole QW formulation in patients with schizophrenia
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2022-04-06; most recent amendment 2024-10-29.
Status change: Recruiting → Active, Not Recruiting 2024-10-29
Trial Details
NCT Number NCT05326347
Lead Sponsor Otsuka Pharmaceutical Co., Ltd.
Conditions Schizophrenia
Enrollment 190 participants
Start Date 2022-05-31
Primary Completion 2025-08 (estimated)
Study Completion 2025-09 (estimated)
Updated on ClinicalTrials.gov 2024-10-30